EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

Antonin Levy*, Lizza E. L. Hendriks, Thierry Berghmans, Corinne Faivre-Finn, Matteo GiajLevra, Niccolo GiajLevra, Baktiar Hasan, Alessia Pochesci, Nicolas Girard, Laurent Greillier, Sylvie Lantuejoul, John Edwards, Mary O'Brien, Martin Reck, Benjamin Besse, Silvia Novello, Anne-Marie C. Dingemans*, EORTC Lung Cancer Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Web of Science)
155 Downloads (Pure)

Abstract

Background: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non esmall-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.

Methods: A European Organisation for Research and Treatment of Cancer Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies' members.

Results: 444 responses were analysed (radiation oncologist: 55% [n = 242], pulmonologist: 15% [n = 66], medical oncologist: 14% [n = 64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n=362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% = 5 metastases. 79% (n = 353) stated that number of organs involved was important for sOM-d, and most (80%, n = 355) considered that only

Conclusion: Although consensual answers were obtained, several issues remain unresolved and will require further research to agree on a sOM-d. (C) 2019 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalEuropean Journal of Cancer
Volume122
DOIs
Publication statusPublished - Nov 2019

Keywords

  • Oligometastasis
  • Non-small cell lung cancer
  • Consensus
  • STEREOTACTIC BODY RADIOTHERAPY
  • EUROPEAN ORGANIZATION
  • PHASE-II
  • THERAPY
  • TRIAL

Cite this